Shares of Eli Lilly plummeted 14% on Thursday, pacing what would be the stock’s largest loss in decades after the pharmaceutical giant unveiled data for its obesity treatment pill that fell behind ...

Quarterly sales of Mounjaro, Zepbound come in above analyst estimates Shares decline over 10% as late-stage data for oral drug fails to impress However, shares of the U.S. drugmaker fell over 10% to ...

Eli Lilly is seeing strong growth from its weight loss drugs. Investors are nervous about tariffs on drugs and weak data from its upcoming pipeline. The stock is cheaper but still trades at a premium ...

Eli Lilly's shares have increased by about 10% over the past month. Clinical progress in the past few weeks has helped solidify its lead in the weight loss market. The company's prospects remain ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the year. By Gina Kolata People who were overweight or had obesity lost a ...

HSBC analysts had a reduce rating on Lilly shares. It's now a hold. There are no longer any sell ratings on Eli Lilly after HSBC upgrade. The bear case for Eli Lilly has now played out following the ...

Patients on Eli Lilly & Co.’s experimental diabetes pill lost more weight and had better blood sugar control than those on an older, approved rival from Novo Nordisk A/S in the first head-to-head ...

Eli Lilly & Co.’s obesity pill prompted enough weight loss in a large clinical trial to be meaningful for patients and have far-reaching implications for the field, doctors said. The US drugmaker’s ...